Finance Rotational Program (2026) at Clairo

Milwaukee, Wisconsin, United States

Apply Now

Not SpecifiedCompensation

Entry Level & New GradExperience Level

Full TimeJob Type

UnknownVisa

ManufacturingIndustries

Requirements

A Bachelor’s Degree in Finance, Accounting, Business, or another quantitative field
Must be an Undergraduate Senior graduating in December 2025 or May 2026
Must be able to commit to the 3 - 3.5 year program, including one 12-month rotation at one of Clarios' US manufacturing plant locations
Leadership demonstrated through extracurricular activities, employment and/or internship experiences
Authorized to work for any employer in the US without the need for sponsorship, now or in the future

Responsibilities

Assist in preparation of monthly management reports and presentations
Execute timely and accurate preparation of all accounting/financial documents
Identify areas of improvement and take action to implement change as agreed upon by management
Prepare month end journal entries and related ad hoc analysis as needed
Assist with forecasting and strategic plan efforts
Compile and review forecasting results from the regions and work together with the regions to resolve unusual trends or findings
Maintain adequate back-up/support for key assumptions

Skills

Financial Reporting

FP&A

Forecasting

Journal Entries

Month-End Close

Accounting

Audit

Controllership

Risk Management

Tax

Treasury

Clairo

Generates clinical evidence for trials

About Clairo

Clario specializes in generating clinical evidence for medical research by utilizing a comprehensive technology platform. Their services support various types of clinical trials, including decentralized, hybrid, and site-based trials. Clario's approach combines nearly 50 years of experience with a vast network of facilities across nine countries, allowing them to conduct a significant number of clinical trials and regulatory approvals. What sets Clario apart from competitors is their extensive expertise and the ability to provide a wide range of endpoint technologies, which enhances the quality of evidence produced. The company's goal is to empower partners in the healthcare industry to improve patient outcomes through reliable and rich clinical data.

London, United KingdomHeadquarters

1972Year Founded

$29.9MTotal Funding

GROWTH_EQUITY_VCCompany Stage

Biotechnology, HealthcareIndustries

5,001-10,000Employees

Benefits

Competitive and equitable total rewards package

Physical, mental and financial health and wellness

Flexible working approach

Risks

Increased competition from AI-driven platforms like Medable may threaten Clario's market share.

The IPO filing may lead to investor pressure for rapid financial returns, affecting strategy.

AI integration from ArtiQ poses data privacy and compliance risks, especially in the EU.

Differentiation

Clario offers a comprehensive endpoint technology platform for diverse clinical trial models.

The company has nearly 50 years of experience in clinical trial technology solutions.

Clario's global presence includes 30 facilities across North America, Europe, and Asia Pacific.

Upsides

Clario's IPO aims for a valuation of over $10 billion, indicating strong market confidence.

The FDA clearance of SpiroSphere® with wireless ECG enhances Clario's clinical trial capabilities.

Clario's acquisition of ArtiQ boosts its AI capabilities in respiratory clinical trials.

Land your dream remote job 3x faster with AI

Try Jobo Free